Methylergometrine
Clinical data | |
---|---|
Trade names | Methergine |
Other names | Methylergonovine; methylergobasin; Methylergobasine; Methylergobrevin; d-Lysergic acid 1-butanolamide; N-[(2S)-1-Hydroxybutan-2-yl]-6-methyl-9,10-didehydroergoline-8β-carboxamide |
AHFS/Drugs.com | International Drug Names |
MedlinePlus | a601077 |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Liver |
Elimination half-life | 30–120 minutes |
Excretion | Mostly bile |
Identifiers | |
| |
JSmol) | |
Melting point | 172 °C (342 °F) |
Solubility in water | Insoluble mg/mL (20 °C) |
| |
| |
(what is this?) (verify) |
Methylergometrine, also known as methylergonovine and sold under the brand name Methergine, is a medication of the
It is on the World Health Organization's List of Essential Medicines.[1]
Medical uses
Obstetric use
Methylergometrine is a smooth muscle constrictor that mostly acts on the uterus. It is most commonly used to prevent or control excessive bleeding following childbirth and spontaneous or elective abortion, and also to aid in expulsion of retained products of conception after a missed abortion (miscarriage in which all or part of the fetus remains in the uterus) and to help deliver the placenta after childbirth. It is available as tablets or injection (IM or IV) or in liquid form to be taken orally.[2][3][4]
Migraine
Methylergometrine is sometimes used for both prevention[5] and acute treatment[6] of migraine. It is an active metabolite of methysergide.[7] In the treatment of cluster headaches, methylergometrine has been initiated at a dose of 0.2 mg/day, rapidly increased to 0.2 mg three times per day, and increased to a maximum of 0.4 mg three times per day.[7]
Contraindications
Methylergometrine is contraindicated in patients with
Side effects
Adverse effects include:[2]
- Nausea, vomiting, and diarrhea
- Dizziness
- Pulmonary hypertension[citation needed]
- Coronary artery vasoconstriction
- Severe systemic hypertension (especially in patients with pre-eclampsia)
- Convulsions
In excessive doses, methylergometrine can also lead to cramping,
Interactions
Methylergometrine likely interacts with drugs that inhibit the liver enzyme
Pharmacology
Pharmacodynamics
Methylergometrine is an
Methylergometrine is a
Methylergometrine is an agonist of the serotonin 5-HT2B receptor and is maybe linked to
Site | Affinity (Ki [nM]) | Efficacy (Emax [%]) | Action |
---|---|---|---|
5-HT1A | 1.5–2.0 | ? | Full agonist |
5-HT1B | 251 | ? | Full agonist |
5-HT1D | 0.86–2.9 | 70 | Partial agonist |
5-HT1E | 89 | ? | Full agonist |
5-HT1F | 31 | ? | Full agonist |
5-HT2A | 0.35–1.1 | ? | Full agonist |
5-HT2B | 0.46–2.2 | ? | Full or partial agonist |
5-HT2C | 4.6–43.7 | ? | Full agonist |
5-HT3 | ? | – | – |
5-HT5A | ? | 24.4[13] | Full agonist[13] |
5-HT6 | ? | ? | Full agonist |
5-HT7 | 11–52 | ? | Full agonist |
Notes: All sites are human except 5-HT1B (rat) and 5-HT7 (guinea pig).[10][11] |
Chemistry
Methylergometrine, also known as d-lysergic acid 1-butanolamide, is a
References
- hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ ISBN 978-3-85200-181-4.
- ISBN 3-8047-1763-2.
- ^ "Methergin". Fachinformation des Arzneimittel-Kompendium der Schweiz (in German).[permanent dead link]
- S2CID 22433355.
- PMID 19895705.
- ^ S2CID 34063682.
- ^ "Methylergonovine Maleate Monograph for Professionals - Drugs.com". drugs.com. Archived from the original on 2016-09-20.
- ISBN 978-905702375-0.
- ^ a b c "PDSP Database - UNC". pdsp.unc.edu. Archived from the original on 16 April 2021. Retrieved 15 January 2022.
- ^ a b c "PDSP Database - UNC". pdsp.unc.edu. Archived from the original on 16 April 2021. Retrieved 15 January 2022.
- ^ ISBN 978-0-08-054111-2.
- ^ PMID 35835867.
- ^ PMID 7420432.
- PMID 24361689.
- PMID 11104741.
- S2CID 266103427. 2663.
- ISBN 978-1-4200-0113-6.
- ISBN 9780429219764. Archived from the original(PDF) on 2021-04-16.